Forward looking statements disclaimer
This presentation contains forward-looking statements that are subject to many risks and uncertainties. These statements, among other things, relate to our business strategy, goals and expectations concerning our products, future operations, prospects, plans and objectives of management. The words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will" and similar terms and phrases are used to identify forward-looking statements in this presentation. These statements and other statements regarding our future plans constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1955. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond OpGen's control, and that may cause results to differ materially from expectations.
Factors that could cause results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and service offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, including our November 2020 private placement, the realization of expected synergies from our business combination transaction with Curetis GmbH, the successful integration of our company with the operations and business of Curetis GmbH and its subsidiaries and the implementation of the combined company's strategic and business goals and objectives, the impact of COVID-19 on our operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the ability to comply with the complexities of operating a global business, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen and its group companies:
Striving to innovate molecular microbiology
Rapid Pathogen Detection For Life Threatening Infections
Broad Pathogen & Antimicrobial Resistance (AMR) Marker Coverage
AI-Powered AMR Prediction & Bioinformatics
OpGen's combined portfolio: Synergistic products & capabilities
Unyvero Platform & Syndromic Tests
Acuitas Tests & Acuitas Lighthouse
Ares Genetics NGS &
Direct sales in U.S., European and China distribution with partners; 26 distributors covering 45 countries; CoV-2 test kit distribution in EMEA
Unyvero FDA-cleared platform for lower respiratory tract infection (LRT & LRT BAL) as well as 5 CE IVD tests; Unyvero A30 RQ platform in development
Acuitas AMR Gene Panel pending FDA clearance (isolates) to improve antibiotic decision making;
Lighthouse knowledge base deployed for public health useAres Technology for AI-powered AMR prediction combining ARESdb with NGS; Strategic partnerships with globally leading IVD & pharma companies
This is an excerpt of the original content. To continue reading it, access the original document here.